Head-To-Head Contrast: NeuroPace (NPCE) vs. The Competition

NeuroPace (NASDAQ:NPCE) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its peers? We will compare NeuroPace to similar companies based on the strength of its institutional ownership, profitability, dividends, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares NeuroPace and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
NeuroPace Competitors	-278.38%	-150.31%	-21.96%

Valuation and Earnings

This table compares NeuroPace and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
NeuroPace	$106.99 million	-$21.47 million	-21.65
NeuroPace Competitors	$1.89 billion	$137.77 million	10.83

NeuroPace’s peers have higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.2% of NeuroPace shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for NeuroPace and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1	1	7	1	2.80
NeuroPace Competitors	4261	10487	18223	825	2.46

NeuroPace presently has a consensus price target of $19.33, suggesting a potential upside of 56.67%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.06%. Given NeuroPace’s stronger consensus rating and higher probable upside, analysts plainly believe NeuroPace is more favorable than its peers.

Volatility & Risk

NeuroPace has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, NeuroPace’s peers have a beta of 2.55, meaning that their average stock price is 155% more volatile than the S&P 500.

Summary

NeuroPace beats its peers on 9 of the 13 factors compared.

About NeuroPace

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.